Table 2

Quality assessment of vaccine trials for immunization against – Shigella

Quality Assessment

Summary of Findings


Directness

No of events


No of Studies

Design

Limitations

Consistency

Generalizability to population of interest

Generalizability to intervention of interest

Intervention

Control

Risk Ratio


Efficacy against morbidity, Shigella Infection (S.Flexneri): Low-outcome-specific quality


03 [35,38,40]

RCT

Random effect model. Insignificant results

Two studies show consistent benefit

Two studies were from developed countries

Two used oral vaccine while one used intramuscular

56

107

0.72 (0.37, 1.39)b

02 [35,38]

RCT

Random effect model. Insignificant results

One study shows significant benefit

One study from developed country

Oral Vaccines

49

99

0.67 [0.28, 1.59]b

01 [40]

RCT

Only one study

Study was conducted in Israel

Parenteral Vaccine

07

08

0.92 [0.33, 2.53]


Efficacy against morbidity, Shigella Infection (S.Sonnei): Low-outcome-specific quality


03 [35,38,40]

RCT

Random effect model. Insignificant results

Two studies show consistent benefit

Two studies were from developed countries

Two used oral vaccine while one used intramuscular

39

94

0.47 (0.12, 1.85)b

02 [35,38]

RCT

Random effect model. Insignificant results

One study shows significant benefit

One study from developed country

Oral Vaccines

10

56

0.39 [0.04, 4.33]b

01 [40]

RCT

Only one study

Study was conducted in Israel

Parenteral Vaccines

29

38

0.73 [0.45, 1.17]


One or more Adverse events (S.Flexneri): Low outcome-specific quality


02 [36,41]

RCT

None

inconsistent results

Both from developing countries

45

08

1.58(0.81, 3.07)a


a: Fixed Effect Model

b: Random Effect Model

Das et al. BMC Public Health 2013 13(Suppl 3):S11   doi:10.1186/1471-2458-13-S3-S11

Open Data